Searched for
BIOPHARMACEUTICAL PIPELINE
AstraZeneca 'magic' faces rare test after trial failure, share slideAstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted...- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- Global Market: Hong Kong IPO boom draws rising interest from overseas companiesHong Kong's stock market is seeing more foreign companies file for listings. Firms from countries like Indonesia and South Korea are explor...
- Bayer to buy Perfuse Therapeutics in up to $2.45 billion dealBayer is set to acquire Perfuse Therapeutics in a deal valued up to $2.45 billion. This strategic move aims to enhance Bayer's eye care tre...
- Sanofi buys US biopharma group Blueprint in $9.1 billion dealSanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt,...
- AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...
- Britain's GSK to buy Affinivax for up to $3.3 bln in vaccines pushGSK, the world's largest vaccine maker by sales, has been under pressure to shore up its pipeline. Last month, it indicated an appetite for...
- Cipla receives USFDA nod to market Lanreotide injection in American marketThe company said it has received final approval for Lanreotide Injection from the US Food and Drug Administration (USFDA). The FDA approval...
- The opportunity in biosimilars is here, one has to grab it: Debayan Ghosh, Epygen Biotech“By 2020, the biopharmaceutical industry will be about $250 billion.”
- Kurt Stoeckli to head Glenmark's global research portfolioBased out of Switzerland, Stoeckli will lead Glenmark’s global research portfolio, including biologics (NBEs) and small molecules (NCEs), t...
- Vyome Biosciences gets Rs 93cr in Series C"The company will utilise these funds predominantly to advance the clinical development of its lead product and continue to develop other p...
- Suven Life Sciences gets patents for neurodegenerative drugBiopharmaceutical firm Suven Life Sciences said it has been granted one patent each by the US, Israel and Macau for a drug used for neuroge...
- Biopharmaceutical Suven Life Sciences gets patents for neurodegenerative drugWith these new patents for treatment of neurodegenerative diseases, Suven has a total of 18 granted patents from Mexico and 20 from Singapo...
- Suven Life Sciences Q1 net profit up by 137%Suven Life Sciences Ltd net profit rise by 137% for Q1. Company to go ahead with amalgamation of Suven Nishtaa Pharma Pvt Ltd with Suven Li...
- Dr Reddy's, Merck to jointly develop biosimilarsmanufacturing of the compounds and will lead phase-III development.
- Reliance Life Sciences bets big on biosimilarsReliance Life Sciences (RLS), a company promoted by Reliance Industries’ chairman, Mukesh Ambani, is looking at biopharmaceuticals as a hug...
- Recession not to hit clinical trials: CROsIndian clinical research organisations do not see any near-term impact of recession as large pharma customers such as AstraZeneca and Glaxo...
- Zenotech to invest over Rs 90 cr in R&DGeneric biopharmaceutical company Zenotech Laboratories is set to invest over Rs 90 crore to strengthen its R&D pipeline.
- Zenotech plans to invest over Rs 90 crore in R&DHyderabad-based generic biopharmaceutical company Zenotech Laboratories is set to invest over Rs 90 crore to strengthen its R&D pipeline.
- Intas mfg unit gets EU-GMP certificationIntas Biopharmaceuticals Ltd (IBPL) has received European Union-good manufacturing practices (EU-GMP) certification for its manufacturing f...
Load More
